Artiva Biotherapeutics, Inc. Common Stock (ARTV)

Artiva Biotherapeutics, Inc. is an innovative biotechnology company specializing in the development of advanced cell therapies, particularly targeting cancer through its proprietary natural killer (NK) cell platform. The company boasts a robust pipeline addressing both hematologic and solid tumors, reflecting its dedication to innovation within the rapidly evolving immuno-oncology space. With a focus on scientific excellence and strategic partnerships, Artiva is well-positioned to drive significant advancements in cancer treatment, aiming to enhance patient outcomes as its clinical candidates progress through trials.